MASC 2.0, un outil d'évaluation multicritère pour estimer la contribution des systèmes de culture au développement durable

International audienceCurrent changes in the field of agriculture encourage stakeholders to envision new and moresustainable production methods. For this purpose, tools are needed to assess the proposed or newlydesigned solutions before they are taken to the fields and disseminated. MASC 2.0 is a multi-criteriaassessment tool designed to assess the performance of cropping systems in terms of theirsustainability. It was based on a decision support system (DEXi) which aggregates 39 qualitative criteriain a single tree. This tool applies to a wide range of situations. It can therefore be used to identify thebest cropping systems in a given territory (ex post assessment) or design prototypes of croppingsystems (ex ante assessment). Thanks to its flexibility, MASC 2.0 offers users the opportunity topropose their own vision of sustainable development by changing the weight given to each evaluationcriterion. Its friendly and simple interface makes this tool a privileged support for exchanges andmediation between researchers, extension workers, farmers, and public authorities. Its main drawbacksare the time spent to fill in all the criteria and the inherent limitations related to the given scale (croppingsystem) in relation to the larger scales more often used to handle sustainable development issues.Les changements actuels du contexte agricole encouragent les différents acteurs à réfléchir à de nouveaux modes de production plus durables. Pour y parvenir, des outils sont nécessaires pour évaluer les solutions identifiées ou nouvellement conçues avant leur expérimentation et leur diffusion. MASC 2.0 est un outil d'évaluation multicritère des performances des systèmes de cultures assolées du point de vue de leur contribution au développement durable. Il a été développé sur un logiciel d'aide à la décision DEXi qui agrège dans une arborescence les 39 critères qualitatifs retenus pour l'évaluation. MASC 2.0 peut être utilisé pour repérer les systèmes actuels les plus performants dans un contexte donné (évaluation a posteriori). Il permet aussi de classer des systèmes de culture conçus par prototypage (évaluation a priori). Par sa flexibilité, MASC 2.0 offre la possibilité aux utilisateurs de décliner leur propre vision du développement durable en modifiant le poids accordé à chaque critère d'évaluation. L'interface du modèle, conviviale et simple d'utilisation, en fait un support d'échanges et de médiation privilégié entre chercheurs, conseillers agricoles, agriculteurs et pouvoirs publics. Ses principaux inconvénients résident dans le temps nécessaire pour renseigner tous les critères et dans les limites intrinsèques liées à l'échelle considérée pour traiter des questions de développement durable, souvent abordées à des échelles plus larges

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Introduction: Targeted therapy in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET amplifications has improved patients’ outcomes. The development of more potent MET kinase inhibitors could further benefit these patients. The aim of this trial is to determine the safety and recommended phase 2 dose (RP2D) of OMO-1 (an oral dual MET kinase/OCT-2 inhibitor) and to assess preliminary clinical efficacy in METex14-positive NSCLC and other MET-positive solid tumors.// Materials and Methods: This was a first-in-patient, open-label, multicenter study of OMO-1 in patients with locally advanced or metastatic solid malignancies. A standard 3 + 3 dose escalation design was utilized starting at a dose level of 100 mg BID continuously. Preliminary efficacy was investigated in patients with METex14-positive NSCLC, and MET amplified NSCLC and other solid tumors (MET basket).// Results: In the dose-escalation part, 24 patients were included in 5 dose levels ranging from 100 mg twice daily (BID) to 400 mg BID. Most common adverse events (≥ 20%) were nausea, fatigue, vomiting, increased blood creatinine, and headache. The RP2D was determined at 250 mg BID. In the expansion cohorts, 15 patients were included (10 in METex14-positive NSCLC cohort and 5 in MET basket cohort) and received either 200 or 250 mg BID. Eight out of the 10 patients with METex14 positive NSCLC had stable disease as the best response.// Conclusion: OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Introduction: Targeted therapy in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET amplifications has improved patients' outcomes. The development of more potent MET kinase inhibitors could further benefit these patients. The aim of this trial is to determine the safety and recommended phase 2 dose (RP2D) of OMO-1 (an oral dual MET kinase/OCT-2 inhibitor) and to assess preliminary clinical efficacy in METex14-positive NSCLC and other MET-positive solid tumors. Materials and Methods: This was a first-in-patient, open-label, multicenter study of OMO-1 in patients with locally advanced or metastatic solid malignancies. A standard 3 + 3 dose escalation design was utilized starting at a dose level of 100 mg BID continuously. Preliminary efficacy was investigated in patients with METex14-positive NSCLC, and MET amplified NSCLC and other solid tumors (MET basket). Results: In the dose-escalation part, 24 patients were included in 5 dose levels ranging from 100 mg twice daily (BID) to 400 mg BID. Most common adverse events (≥ 20%) were nausea, fatigue, vomiting, increased blood creatinine, and headache. The RP2D was determined at 250 mg BID. In the expansion cohorts, 15 patients were included (10 in METex14-positive NSCLC cohort and 5 in MET basket cohort) and received either 200 or 250 mg BID. Eight out of the 10 patients with METex14 positive NSCLC had stable disease as the best response. Conclusion: OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients.</p

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not been previously evaluated. Methods: In a phase 1b study (NCT02099058), adult patients (≥18 y) with advanced NSCLC received combination therapy with Teliso-V (1.6, 1.9, or 2.2 mg/kg, every 2 wk) plus nivolumab (3 mg/kg, 240 mg, or per locally approved label). The primary objective was to assess safety and tolerability; secondary objectives included the evaluation of antitumor activity. Results: As of January 2020, a total of 37 patients received treatment with Teliso-V (safety population) in combination with nivolumab; 27 patients (efficacy population) were c-Met immunohistochemistry-positive. Programmed death-ligand 1 (PD-L1) status was evaluated in the efficacy population (PD-L1-positive [PD-L1+]: n = 15; PD-L1-negative [PD-L1-]: n = 9; PD-L1-unknown: n = 3). The median age was 67 years and 74% (20 of 27) of patients were naive to immune checkpoint inhibitors. The most common any-grade treatment-related adverse events were fatigue (27%) and peripheral sensory neuropathy (19%). The pharmacokinetic profile of Teliso-V plus nivolumab was similar to Teliso-V monotherapy. The objective response rate was 7.4%, with two patients (PD-L1+, c-Met immunohistochemistry H-score 190, n = 1; PD-L1-, c-Met H-score 290, n = 1) having a confirmed partial response. Overall median progression-free survival was 7.2 months (PD-L1+: 7.2 mo; PD-L1-: 4.5 mo; PD-L1-unknown: not reached). Conclusions: Combination therapy with Teliso-V plus nivolumab was well tolerated in patients with c-Met+ NSCLC with limited antitumor activity

Immunogénicité des exosomes de cellules dendritiques (résultats cliniques et précliniques)

PARIS-BIUP (751062107) / SudocSudocFranceF

Agrophysiologie du pois protéagineux - Applications à la production agricole

National audienc

Évaluer la durabilité de systèmes de culture en agriculture de conservation à Madagascar (région du lac Alaotra) avec MASC-Mada

Evaluating cropping systems depends on the perspective and scale considered. An agronomic point of view is often considered with the assessment of the impacts of the cropping system at the field scale, or an economic point of view with the consequences of implementing a cropping system on the farm. Tools have been developed to enable a more integrative assessment of cropping systems. This is the case of the MASC (R) model which, using multicriteria evaluation, estimates the sustainability of cropping systems from environmental, economic and social perspectives. MASC-Mada was developed specifically for upland cropping systems in Madagascar. It has been used to compare conservation agriculture cropping systems with conventional cropping systems. The results, confronted to the opinion of farmers, show that conservation agriculture systems are generally more sustainable than conventional systems but a mixed system combining the use of cover crops and less frequent tillage would better take social and economic aspects into account.L’évaluation des systèmes de culture de´pend du point de vue et de l’échelle envisagés. Un point de vue agronomique est souvent adopté avec l’évaluation des impacts de différents systèmes à l’échelle de la parcelle, ou un point de vue économique avec les conséquences d’un système de culture sur le fonctionnement de l’exploitation agricole. Des outils ont néanmoins été développés pour permettre une évaluation plus intégrative des systèmes de culture. C’est le cas du modèle MASC1 qui permet, par une approche multicritère, d’évaluer la durabilité des systèmes de culture à la fois d’un point de vue environnemental, économique et social. MASC-Mada, développe pour les systèmes de culture pluviaux à Madagascar, a été utilisé pour comparer des systèmes en agriculture de conservation avec des systèmes conventionnels. Les résultats des évaluations, confrontés aux points de vue des agriculteurs, révèlent que les systèmes en agriculture de conservation sont globalement plus durables que les systèmes traditionnels, mais qu’un système mixte alliant utilisation de plantes de couverture et des labours moins fréquents prendrait mieux en compte les aspects sociaux et économiques

L'évaluation multicritère des systèmes agricoles : une révolution des méthodes

L'évaluation multicritère des systèmes agricoles : une révolution des méthode

Sensitivity analysis of DEXi type models applied to design cropping systems

National audienc